To print: Select File and then Print from your browser's menu

Title: FDA Approves Eloxatin (Oxaliplatin) for Treatment of Advanced Colorectal Cancer

"FDA Approves Eloxatin (Oxaliplatin) for Treatment of Advanced Colorectal Cancer"

LOS ANGELES, CA -- January 12, 2004 -- Sanofi-Synthelabo today announced that Eloxatin® (oxaliplatin for injection) received approval from the U.S. Food and Drug Administration (FDA) for the first-line treatment of advanced colorectal cancer. The first-line Eloxatin-based regimen, Folfox, demonstrated improved survival and a lower incidence of common chemotherapy-related side effects compared with a standard treatment regimen, IFL. More news: - Eloxatin (as part of the FOLFOX4 regimen) also is being studied in combination with the experimental oral angiogenesis inhibitors Avastin (Genentech) and PTK/ZK (Novartis/Schering AG). Oral angiogenesis inhibitors are agents that effectively target the tumor blood vessels, slowing tumor growth and spread. - Extensive worldwide clinical development program is ongoing to explore the benefit of Eloxatin in other types of cancers, primarily pancreatic and gastric cancer. SOURCE: Sanofi-US.

Copyright © 2010 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.